FIDAS-3 is a stilbene derivative and is a potent Wnt inhibitor with an IC 50 of 4.9 μM for methionine S-adenosyltransferase 2A (MAT2A) . FIDAS-3 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-3 has anticancer activities In Vitro FIDAS-3 (3 μM; 7 days; LS174T cells) treatment significantly inhibits the proliferation of LS174T cells. FIDAS-3 (3-10 μM) treatment inhibits the expression of c-Myc and cyclinD1 in LS174T CRC cells. And FIDAS-3 induces the expression of cell cycle inhibitor, p21 WAF1/CIP1. FIDAS-3 (10 μM; 36 h) treatment reduces the levels of both S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in LS174T cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: LS174T colorectal cancer (CRC) cells Concentration: 3 μM Incubation Time: 7 days Result: Significantly inhibited the proliferation of LS174T cells. In Vivo FIDAS-3 (20 mg/kg; intraperitoneal injection; daily; for one months; C57BL/6J athymic nude mice) treatment significantly inhibits the growth of xenograft tumors. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6J athymic nude mice (6-8 week) injected with LS174 cellsDosage: 20 mg/kg Administration: Intraperitoneal injection; daily; for one months Result: Significantly inhibited the growth of xenograft tumors. Form:Solid IC50& Target:IC50: 4.9 μM (Methionine S-adenosyltransferase 2A (MAT2A))